 SAN DIEGO, Aug. 16, 2021 GLOBE NEWSWIRE -- Turning Point Therapeutics, Inc. NASDAQ: TPTX, a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced initiation of the first cohort of its Phase 1b2 TRIDENT-2 combination study of lead investigational drug repotrectinib. The initial cohort will investigate repotrectinib in combination with MEK-inhibitor trametinib in KRAS G12D mutated advanced solid tumors. 